Irinotecan Hydrochloride Teva

Irinotecan, the active ingredient in Irinotecan Hydrochloride Teva, is a topoisomerase I inhibitor presented as a sterile powder for reconstitution for intravenous injection. It is used in the treatment of metastatic colorectal cancer in adult patients, typically administered by a qualified healthcare professional in a clinical setting.

GNH USA supplies Irinotecan Hydrochloride Teva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to oncology centres, hospitals and specialty pharmacies worldwide under strict quality and regulatory standards, and ensuring timely delivery.

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer.

Metastatic colorectal cancer: used as part of combination chemotherapy regimens to improve disease control and survival outcomes.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea, often severe - Neutropenia (low white blood cell count) - Fatigue and weakness - Alopecia (hair loss) - Mild liver enzyme elevations

Serious or Rare Side Effects: - Febrile neutropenia (infection with fever) - Severe colitis or intestinal perforation - Anaphylactic or severe allergic reactions - Hepatic failure or marked transaminase rise - Pulmonary toxicity (interstitial pneumonitis) - Severe electrolyte disturbances

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Blood count monitoring: perform regular complete blood counts to detect neutropenia. - Liver function assessment: evaluate hepatic enzymes prior to and during treatment. - Bowel health evaluation: assess for pre‑existing gastrointestinal disease to reduce risk of severe diarrhea. - Hypersensitivity screening: avoid use in patients with known allergy to irinotecan or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan's efficacy and safety can be altered by concomitant medicines.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may markedly reduce SN‑38 exposure. - Concurrent use with other myelosuppressive agents can increase risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase SN‑38 levels, requiring dose adjustment. - Anticholinergic drugs can exacerbate irinotecan‑induced diarrhea. - Warfarin may have altered anticoagulant effect; monitor INR closely.